Spotlight
Clinical
Articles
CME/CE
Subscribe
BAC free glaucoma therapy welcomed in Japan
The Ministry of Health, Labour and Welfare in Japan has approved Alcon's treatment for glaucoma and ocular hypertension, TRAVATANZ 0.004%.
The Ministry of Health, Labour and Welfare in Japan has approved Alcon's treatment for glaucoma and ocular hypertension, TRAVATANZ 0.004%.
TRAVATANZ is the first prostaglandin analogue that does not contain benzalkonium chloride (BAC), a preservative that is commonly used in topical ocular medications. Recent research has suggested that BAC could negatively affect the ocular surface. To this end, Alcon developed TRAVATANZ as a BAC free version of it glaucoma therapy, TRAVATAN.
TRAVATANZ was approved as TRAVATAN Z in the US in 2006.
Related Videos
Related Content
